Although Saxenda is the first generic GLP-1 to hit the US market, its sales will likely be overshadowed by next-gen drugs ...

By comparison, Saxenda (liraglutide) prompted similar weight loss in only 29% of those being treated for obesity and 12% being treated for type 2 diabetes.

The FDA has approved the first generic GLP-1 specifically indicated for weight loss, according to a press release from Teva Pharmaceuticals. As Healio previously reported, Teva Pharmaceuticals ...

In December 2024, Teva also secured FDA approval for the other liraglutide brand Victoza, indicated for type 2 diabetes.

Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the ...

A Blue Cross Blue Shield study of one decade worth of claims for Saxenda and Wegovy found 58% of patients quit the weight-loss drugs after 12 weeks.

Medicare drug plans don’t cover Saxenda because Medicare doesn’t cover GLP-1 agonists when prescribed for weight loss.

The weight-loss drug liraglutide (Saxenda) helped obese children lower their BMI and reach a healthier weight, researchers report.

Saxenda is a prescription drug used to help with weight loss. Learn about the common, mild, and serious side effects it can cause and how to manage them.

The demand for weight loss operations dropped sharply last year as the number of people opting for anti-obesity drugs such as Wegovy and Saxenda more than doubled, a study published Friday found ...